CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL) at Sheba Medical Center
O que está incluído neste pacote
Procedimentos médicos
- Terapia com células T CAR
- Exames de sangue
- Exame de sangue para bioquímica
- Biópsia
- Tomografia Computadorizada
- Consulta com um médico
- Consulta com um oncologista
- Consulta com um hematologista
- Consulta com um imunologista
- Consulta com um hematologista pediátrico
- Hemograma completo com marcadores tumorais e proteinograma
- Angiotomografia
- Eletrocardiograma (ECG)
- Exame de acompanhamento
- Cuidados pós-operatórios
- Exames pré-operatórios
- PET/TC
- Consulta com um onco-hematologista
- Serviços de enfermagem 24 horas
- 3 refeições por dia pelo nutricionista
Duração
- 21 dias no hospital
Acomodação
Hospitalização
Transporte
Transfer aeroporto-clínica-aeroporto
Informações adicionais
CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL) at Sheba Medical Center
For patients diagnosed with Acute Lymphoblastic Leukemia (ALL), especially those with relapsed or treatment-resistant disease, access to advanced therapy can be life-changing.
Sheba Medical Center, one of the world’s leading hospitals, offers state-of-the-art CAR-T cell therapy, providing new hope where conventional treatments may no longer be effective.
Sheba is recognized as a global leader in CAR-T therapy for ALL, particularly in pediatric and young adult patients, combining cutting-edge science with extensive clinical experience.
A Faster Path to Life-Saving Treatment
At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality, critical in fast-progressing diseases like ALL.
• Apheresis – collection of the patient’s T-cells
• Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
• Infusion – reinfusion of modified cells designed to target and eliminate leukemia cells
By keeping the entire process in-house, treatment can begin in approximately 10 days, significantly faster than many international centers.
CAR-T therapy acts as a “living drug,” continuing to work in the body and offering the potential for deep and lasting remission.
All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology.
Outstanding Outcomes That Offer Real Hope
Sheba is a world leader in pediatric CAR-T for ALL, with exceptional clinical results:
• Up to ~90% remission in pediatric patients
• ~80% in young adults (up to 23 years)
• ~70% in adult patients
These outcomes provide a powerful treatment option and a second chance for patients with limited alternatives.
Why Patients Choose Sheba
• Rapid access to CAR-T therapy – treatment initiation in ~10 days
• Extensive experience – leading CAR-T program in the region
• Dedicated CAR-T units – specialized care with 24/7 monitoring
• Multidisciplinary expertise – hematology, oncology, and immunotherapy teams working together
• Full international support – medical review, travel coordination, and patient assistance
Comprehensive, Personalized Care
Each patient undergoes a full diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and complete medical assessment, ensuring a precise, individualized treatment plan.
Services are available in English, Russian, and Arabic, providing a seamless experience for international patients and their families.
A Global Leader in Advanced Leukemia Care
By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for ALL worldwide, offering patients not just treatment, but a real opportunity for remission and renewed life.
Assistência Bookimed 24/7
- Coordenador médico pessoal
- Arranjos de viagem médica — reserva de passagens aéreas e quartos de hotel com preços especiais de parceiros
- Defesa do paciente durante a viagem médica
Preço do programa
O que NÃO está incluído neste pacote
Médico
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Como estamos indo?
Sobre a clínica
A terapia com células CAR-T no Sheba Medical Center em Tel Aviv, Israel, pode custar cerca de US$ 63.100 pelo programa completo. O hospital está entre os 10 melhores do mundo e oferece este tratamento avançado sob a coordenação do Prof. Arnon Nagler, um renomado especialista em transplante de medula óssea.
Sobre o Tratamento
A terapia com células CAR-T é uma abordagem inovadora para leucemia, linfoma e mieloma múltiplo. O processo envolve a coleta das células T do paciente, sua modificação genética em laboratório e a reinfusão após a quimioterapia. O procedimento exige 21 dias de internação hospitalar, com possibilidade de permanência na UTI.
O que está incluído
- Avaliação abrangente (US$ 5.000 - US$ 10.000)
- Coleta de células via aférese (US$ 6.600)
- Preparação laboratorial das células modificadas (US$ 20.000)
- Quimioterapia de condicionamento (US$ 5.000)
- Internação de 21 dias (US$ 31.500)
- Avaliação pós-tratamento (US$ 3.000 - US$ 5.000)
Preparação e Recuperação
Os pacientes necessitam de biópsia de medula óssea, exames de PET/CT e exames de sangue antes do tratamento. Após a infusão, ocorre o monitoramento diário para a síndrome de liberação de citocinas. A permanência total recomendada em Israel é de 4 a 6 semanas. Vale ressaltar que o CAR-T para mieloma ainda é experimental.
O Sheba Medical Center atende 1,5 milhão de pacientes anualmente e oferece atendimento multilíngue. É necessário um depósito de US$ 50.000 a US$ 60.000 antes da chegada. Entre em contato com o hospital para avaliar se esta terapia é adequada para o seu caso.
Pagamento e Recompensas
Não pague por nossos serviços
Efetue o pagamento diretamente na clínica ou na conta bancária oficial dela.
Algumas clínicas podem exigir um depósito como parte de sua política.
Divida seus pagamentos com opções de parcelamento.
Ganhe recompensas por indicar amigos ao Bookimed.